Notably, the clinical trials MAGMA and JCOG1703 further demonstrated that some treatment regimens for newly diagnosed GBMs ...

Chief Scientific Officer Stephen Connelly outlined new preclinical data during a company webinar focused on the relationship ...

Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with ...

Five years into the rollout of Extended Producer Responsibility schemes for packaging, early policy experimentation is giving ...

Median PFS at 7.0 months, median DoR is 9.3 months with DCR of 79.5% in metastatic NSCLC patients with acquired resistance to ...

Researchers have built a miniaturized microcomb-driven terahertz wireless communication system that's 90 times smaller than ...

Discusses Positive Interim Results From JADE101 Phase I Healthy Volunteer Study and Development Plans June 1, 2026 8:00 ...

"ASCO26: BMS and J&J debut shining multiple myeloma data" was originally created and published by Pharmaceutical Technology, ...

Median PFS at 7.0 months, median DoR is 9.3 months with DCR of 79.5% in metastatic NSCLC patients with acquired ...

CEO Abizer Gaslightwala highlights promising ASCO data demonstrating synergy of AKTX-101 with adagasrib in KRAS-driven ...

PWM relays allow engineers to go beyond simple "on-off" control to realize significant power savings and reduced heat ...